Dong-A ST 2026 Q1 Consolidated Sales Up 11.8%, Operating Profit Swings to Black

Consolidated Q1 2026 revenue KRW 203.6bn (+11.8% YoY), operating profit KRW 7.8bn (swing to profit), net profit KRW 7.9bn (swing to profit)
Debt ratio improved to 98.8% (from 110.2% at end of prior year)
ETC sales up 22.8% (driven by Jakubo and Diperelin); overseas sales down 17.5% (Can-Bac-Su affected by Cambodia/Thailand conflict)
R&D expenses KRW 26.1bn (12.8% of sales); DMB-3115 global marketing approvals completed; DA-1726 obesity phase 1 positive results
Health Insurance suspension lawsuit in second trial, provision of KRW 11.3bn booked (risk)
Standalone: operating profit KRW 10.8bn, net profit KRW 13.9bn